ATE435010T1 - Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien - Google Patents

Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien

Info

Publication number
ATE435010T1
ATE435010T1 AT00986336T AT00986336T ATE435010T1 AT E435010 T1 ATE435010 T1 AT E435010T1 AT 00986336 T AT00986336 T AT 00986336T AT 00986336 T AT00986336 T AT 00986336T AT E435010 T1 ATE435010 T1 AT E435010T1
Authority
AT
Austria
Prior art keywords
treatment
bone
retinoid receptor
receptor antagonists
cartilage
Prior art date
Application number
AT00986336T
Other languages
English (en)
Inventor
Maurizio Pacifici
Roshantha Chandraratna
Original Assignee
Allergan Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Univ Pennsylvania filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE435010T1 publication Critical patent/ATE435010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00986336T 1999-12-15 2000-12-13 Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien ATE435010T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,344 US6313168B1 (en) 1999-12-15 1999-12-15 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
PCT/US2000/033697 WO2001043732A2 (en) 1999-12-15 2000-12-13 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies

Publications (1)

Publication Number Publication Date
ATE435010T1 true ATE435010T1 (de) 2009-07-15

Family

ID=23843560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986336T ATE435010T1 (de) 1999-12-15 2000-12-13 Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien

Country Status (8)

Country Link
US (1) US6313168B1 (de)
EP (2) EP1248602B1 (de)
JP (1) JP4808887B2 (de)
AT (1) ATE435010T1 (de)
AU (1) AU784189B2 (de)
CA (1) CA2394210A1 (de)
DE (1) DE60042496D1 (de)
WO (1) WO2001043732A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111695A1 (en) * 1995-11-06 2002-08-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
WO2001068135A2 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003024473A2 (en) * 2001-09-17 2003-03-27 The University Of Western Ontario Retinoid receptor pan-antagonists for stimulating chondrogenesis
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
FR2847167A1 (fr) * 2002-11-15 2004-05-21 Galderma Res & Dev UTILISATION D'UN ANTAGONISTE DES RECEPTEURS RARs POUR POTENTIALISER L'ACTION DU TGFb
AU2003302070A1 (en) * 2002-11-15 2004-06-15 Galderma Research And Development, S.N.C. USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFBeta
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
ATE423761T1 (de) * 2003-12-26 2009-03-15 Allergan Inc Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
CA2623638A1 (en) 2005-09-30 2007-04-12 Vitae Pharmaceuticals, Inc. Treatment of cancer with specific rxr agonists
CN101472572B (zh) * 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
CN105188753B (zh) 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
DK3000466T3 (en) 2013-05-22 2018-11-26 Univ Yamaguchi INHIBITOR FOR RETINOCHOROIDAL DISEASES
KR102489706B1 (ko) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
MX386643B (es) 2016-03-10 2025-03-19 Io Therapeutics Inc Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas.
EP3426303B1 (de) 2016-03-10 2022-06-15 IO Therapeutics, Inc. Behandlung von muskelerkrankungen mit kombinationen von rxr-agonisten und schilddrüsenhormonen
MX390115B (es) 2016-06-08 2025-03-20 Clementia Pharmaceuticals Inc Metodos para tratar la osificacion heterotopica.
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
UY37806A (es) 2017-07-11 2020-01-31 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0807624B1 (de) 1991-12-18 2009-08-12 The Salk Institute For Biological Studies Retinsäurederivate
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5514825A (en) 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
MXPA01009027A (es) * 1999-03-08 2002-08-30 Basilea Pharmaceutica Ag Antagonistas de retinoide y uso de los mismos.

Also Published As

Publication number Publication date
CA2394210A1 (en) 2001-06-21
DE60042496D1 (de) 2009-08-13
EP1248602B1 (de) 2009-07-01
EP1248602A2 (de) 2002-10-16
WO2001043732A2 (en) 2001-06-21
JP4808887B2 (ja) 2011-11-02
WO2001043732A3 (en) 2002-03-21
US6313168B1 (en) 2001-11-06
AU784189B2 (en) 2006-02-16
EP1645271A1 (de) 2006-04-12
JP2003519103A (ja) 2003-06-17
AU2259301A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
DE60042496D1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
ATE182591T1 (de) 5-ht4 rezeptor antagonisten
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
JO2371B1 (en) 4-phenyl-pyridine derivatives
BR9507910A (pt) Derivados da piperazina como antagonistas de 5-ht1a
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
CO5271691A1 (es) Nuevos compuestos
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60014339D1 (de) Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2087038B1 (es) Nuevas piperidinas con actividad antagonista del paf.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
AU3422800A (en) Use of 5-ht3 receptor antagonists
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
BR0206687A (pt) Método para prevenir e tratar dores viscerais e distúrbios gastrointestinais
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
DK0804186T3 (da) Indolditerpenalkaloidforbindelser
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties